Orsini Becomes Specialty Pharmacy Partner for Priovant's LISRAYA™ Treatment
In an important development for patients suffering from dermatomyositis, Orsini, known for its expertise in rare disease pharmacy solutions, is set to become the specialty pharmacy partner for Priovant's LISRAYA™ (brepocitinib). This newly FDA-approved therapy is a once-daily oral treatment specifically designed for adults afflicted with dermatomyositis, a rare autoimmune condition that manifests through painful skin rashes, debilitating muscle weakness, and serious systemic problems affecting vital organs such as the lungs and heart.
The approval of LISRAYA represents a significant milestone, as it is the first targeted therapy made available for dermatomyositis. The active ingredient, brepocitinib, was thoroughly examined in the VALOR study, which is notable for being the largest placebo-controlled trial focused on dermatomyositis to date. Patients participating in this trial demonstrated meaningful clinical improvement across several measures, which included overall myositis response, skin affliction severity, muscle strength enhancement, and functional disability reduction.
Brandon Tom, CEO of Orsini, emphasized the importance of this new treatment option, stating, "The approval of LISRAYA represents an incredible step forward for these patients and their care journey, and Orsini is thrilled to help meaningfully improve their quality of life." This partnership is expected to significantly ease access to LISRAYA for patients, an essential aspect given the complexities involved in managing rare diseases.
Daniel Herz-Roiphe, Priovant’s Chief Operating Officer, expressed enthusiasm about collaborating with Orsini, highlighting the potential of LISRAYA to transform the treatment landscape for individuals with dermatomyositis. This collaboration combines Orsini's rich experience in rare disease therapies with Priovant's innovative approach, ensuring that patients encounter a streamlined process when securing access to this newly approved medication.
Orsini has been providing compassionate care since 1987, and its continued mission is to partner with innovative biopharmaceutical firms, healthcare providers, and insurance payers to help patients and their family members navigate the complexities of accessing next-generation treatments for rare diseases. Their services encompass comprehensive pharmacy distribution, patient support services, and clinical management.
In addition to enhancing patient support, Orsini has also made considerable strides in the area of home infusion services, thereby allowing patients to receive advanced therapies in the comfort of their homes, an element particularly crucial for those with serious health conditions.
Priovant's LISRAYA is an important addition to the therapeutic options available for dermatomyositis, which has historically lacked robust treatment solutions. The FDA's endorsement signals hope and progress in addressing the unmet medical needs of this patient population.
For potential users of LISRAYA, it is essential to stay informed about safety information and possible risks, including serious infections, cardiovascular events, and malignancies, as outlined in the prescribing information. Physicians will continue to monitor patients closely, especially those with existing health challenges, to ensure the safe administration of the therapy.
In conclusion, the partnership between Orsini and Priovant marks a transformative phase in offering tailored care solutions for patients dealing with the complexities of dermatomyositis. With such advancements, patients can hope for improved health outcomes and a better quality of life, thanks to cutting-edge therapies like LISRAYA.
The approval of LISRAYA represents a significant milestone, as it is the first targeted therapy made available for dermatomyositis. The active ingredient, brepocitinib, was thoroughly examined in the VALOR study, which is notable for being the largest placebo-controlled trial focused on dermatomyositis to date. Patients participating in this trial demonstrated meaningful clinical improvement across several measures, which included overall myositis response, skin affliction severity, muscle strength enhancement, and functional disability reduction.
Brandon Tom, CEO of Orsini, emphasized the importance of this new treatment option, stating, "The approval of LISRAYA represents an incredible step forward for these patients and their care journey, and Orsini is thrilled to help meaningfully improve their quality of life." This partnership is expected to significantly ease access to LISRAYA for patients, an essential aspect given the complexities involved in managing rare diseases.
Daniel Herz-Roiphe, Priovant’s Chief Operating Officer, expressed enthusiasm about collaborating with Orsini, highlighting the potential of LISRAYA to transform the treatment landscape for individuals with dermatomyositis. This collaboration combines Orsini's rich experience in rare disease therapies with Priovant's innovative approach, ensuring that patients encounter a streamlined process when securing access to this newly approved medication.
Orsini has been providing compassionate care since 1987, and its continued mission is to partner with innovative biopharmaceutical firms, healthcare providers, and insurance payers to help patients and their family members navigate the complexities of accessing next-generation treatments for rare diseases. Their services encompass comprehensive pharmacy distribution, patient support services, and clinical management.
In addition to enhancing patient support, Orsini has also made considerable strides in the area of home infusion services, thereby allowing patients to receive advanced therapies in the comfort of their homes, an element particularly crucial for those with serious health conditions.
Priovant's LISRAYA is an important addition to the therapeutic options available for dermatomyositis, which has historically lacked robust treatment solutions. The FDA's endorsement signals hope and progress in addressing the unmet medical needs of this patient population.
For potential users of LISRAYA, it is essential to stay informed about safety information and possible risks, including serious infections, cardiovascular events, and malignancies, as outlined in the prescribing information. Physicians will continue to monitor patients closely, especially those with existing health challenges, to ensure the safe administration of the therapy.
In conclusion, the partnership between Orsini and Priovant marks a transformative phase in offering tailored care solutions for patients dealing with the complexities of dermatomyositis. With such advancements, patients can hope for improved health outcomes and a better quality of life, thanks to cutting-edge therapies like LISRAYA.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.